BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18762814)

  • 1. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance.
    Jhavar S; Bartlett J; Kovacs G; Corbishley C; Dearnaley D; Eeles R; Khoo V; Huddart R; Horwich A; Thompson A; Norman A; Brewer D; Cooper CS; Parker C
    Prostate Cancer Prostatic Dis; 2009; 12(2):143-7. PubMed ID: 18762814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
    BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
    Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
    Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
    Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
    J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.
    Toubaji A; Sutcliffe S; Chaux A; Lecksell K; Hicks J; De Marzo AM; Platz EA; Netto GJ
    Hum Pathol; 2012 Nov; 43(11):1852-65. PubMed ID: 22554381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer.
    Luczynska E; Gasinska A; Wilk W
    Pol J Pathol; 2012 Dec; 63(4):272-7. PubMed ID: 23359198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
    Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
    Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
    Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
    Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies].
    Ojea Calvo A; Mosteiro Cerviño MJ; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A
    Arch Esp Urol; 2004 Oct; 57(8):805-16. PubMed ID: 15560269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
    Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
    In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
    Hameed O; Sublett J; Humphrey PA
    Am J Surg Pathol; 2005 May; 29(5):579-87. PubMed ID: 15832080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research.
    Komiya A; Kato T; Hori T; Fukuoka J; Yasuda K; Fuse H
    Int J Oncol; 2014 Jan; 44(1):195-202. PubMed ID: 24220327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.
    Mazzucchelli R; Barbisan F; Tagliabracci A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Virchows Arch; 2007 Apr; 450(4):371-8. PubMed ID: 17285325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.